Logo
);

Mammalian expression of cancer markers
(industrial collaboration)


Supervisors:
J. Preben Morth, Group Leader
Centre for molecular medicine Norway (NCMM), Forskningsparken.

Theis Sommer R&D project manager, Mohsen Shadidi, R&D manager
SERO AS, Billingstad, Asker.

E-post: [email protected], [email protected]

 

Background – Carcinoma antigen 15-3 (CA15-3) is a marker for tumors of epithelial origin especially breast cancer. It is defined as the glycoprotein that binds with the two monoclonal antibodies DF3 (which recognizes the Mucin 1, MUC1 sequence DTRPAPGS) and 115D8 (which binds to a peptide carbohydrate epitope on the same repeat unit).

It is an early marker present in human serum for systemic reoccurrence after primary treatment. CA15-3 is the highly glycosylated extracellular soluble domain of Mucin 1 (MUC1) expressed primarily on the surface of epithelial cells.1,2

 

Molecular biology techniques you are likely to encounter and could be trained in:

• Growth and maintenance of human cell lines.
• Lab scale expression and purification of native source proteins, with a special focus on CA15-3.
• Transfer of obtained results to large scale production and partitioning in development of expression facilities.
• Biochemical protein characterization including fluorescence spectroscopy. • Crystallization and structural characterization of proteins.

From you we expect
Commitment, scientific curiosity, ability to work independently after 2-3 months and a background in molecular biology/biochemistry/cell biology or similar. We consider laboratory work for a master degree a full time position, minimum 37+ hours a week, you will be expected to spent half your time at NCMM and half at SERO and must therefore be able to communicate to both locations.

Please do not hesitate to contact us for further information.

Find your product



For lot specific documentation enter the 8-digit number included in your user manual


Created with Sketch. My SERO

Need help?
We will assist you


Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×